EHA 2022 | An insight into CTX130: a novel allogeneic CAR-T cell therapy

Name: An insight into CTX130: a novel allogeneic CAR-T cell therapy
Uploaded: 2022-06-10T00:00:00Z
Duration: 1 min 26 s
Description: In this video, Swaminathan Iyer, MD, University of Texas MD Anderson Cancer Center, Houston, TX, briefly explains the CRISPR-CAS9 gene editing process behind CTX130 and how this gene editing process aims to improve the efficacy of this novel CAR-T agent. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Swaminathan Iyer • 10 Jun 2022

EHA 2022

General CAR-T CTX130

In this video, Swaminathan Iyer, MD, University of Texas MD Anderson Cancer Center, Houston, TX, briefly explains the CRISPR-CAS9 gene editing process behind CTX130 and how this gene editing process aims to improve the efficacy of this novel CAR-T agent. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.